FDA is advised to reject wider use of Amgen's Xgeva

02/8/2012 | Reuters

An expert panel urged the FDA not to approve Amgen's Xgeva for delaying the spread of prostate cancer to the bone, saying the drug's benefits do not outweigh the risk of developing osteonecrosis of the jaw. Xgeva provides a meaningful benefit, and is being tested against other cancers, including breast, lung and multiple myeloma, Amgen said. The FDA will issue a final ruling by April 26.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA